ANI Pharmaceuticals, Inc. ANIP NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

70/100

3/7 Pass

SharesGrow Intrinsic Value

Il y a eu 50 transactions d'initiés récentes enregistrées pour ANI Pharmaceuticals, Inc. (ANIP), dont 9 achats et 41 ventes. Le total des achats d'initiés s'élève à $14.28M et le total des ventes d'initiés à $10.77M.

Les initiés notables ayant une activité récente comprennent Mutz Christopher, Cook Meredith, Rowland Thomas Andrew. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.

Transactions d'Initiés — ANIP

Date	Nom	Rôle	Type de Transaction	Actions	Prix Moyen	Valeur	Actions détenues
2026-03-13	Mutz Christopher	Head of Rare Disease	Vente Informative	3,162	$71.64	$226.53K	91,309
2026-03-13	Cook Meredith	Sr. VP, General Counsel & Sec.	Vente Informative	500	$72.62	$36.31K	79,390
2026-03-11	Rowland Thomas Andrew	SVP, Head - Established Brands	Vente Informative	4,772	$74.91	$357.47K	38,730
2026-03-09	Mutz Christopher	Head of Rare Disease	Vente Informative	3,602	$74.18	$267.2K	94,471
2026-03-09	Davis Krista	SVP, Chief HR Officer	Vente Informative	5,087	$74.13	$377.1K	51,946
2026-03-07	Carey Stephen P.	SVP & CFO	Retenue Fiscale RSU	5,150	$74.04	$381.31K	180,393
2026-03-07	Lalwani Nikhil	President & CEO	Retenue Fiscale RSU	17,060	$74.04	$1.26M	404,889
2026-03-07	Gutwerg Ori	SVP, Generics	Retenue Fiscale RSU	3,314	$74.04	$245.37K	81,468
2026-03-07	Mutz Christopher	Head of Rare Disease	Retenue Fiscale RSU	3,314	$74.04	$245.37K	98,073
2026-03-06	Mutz Christopher	Head of Rare Disease	Vente Informative	2,121	$74.22	$157.42K	101,387
2026-03-06	Davis Krista	SVP, Chief HR Officer	Vente Informative	1,485	$75.00	$111.38K	57,033
2026-03-05	Carey Stephen P.	SVP & CFO	Exercice d'Options (Vente)	3,312	$49.51	$163.98K	9,938
2026-03-03	Walsh Patrick D	Director	Vente Informative	6,000	$74.23	$445.38K	52,405
2026-03-03	Gutwerg Ori	SVP, Generics	Vente Informative	2,060	$76.50	$157.59K	84,782
2026-03-02	Mutz Christopher	Head of Rare Disease	Vente Informative	417	$74.00	$30.86K	103,508
2026-02-28	Rowland Thomas Andrew	SVP, Head - Established Brands	Retenue Fiscale RSU	628	$73.90	$46.41K	43,502
2026-02-28	Carey Stephen P.	SVP & CFO	Retenue Fiscale RSU	2,773	$73.90	$204.92K	189,543
2026-02-28	Lalwani Nikhil	President & CEO	Retenue Fiscale RSU	12,217	$73.90	$902.84K	421,949
2026-02-28	Gutwerg Ori	SVP, Generics	Retenue Fiscale RSU	2,221	$73.90	$164.13K	86,842
2026-02-28	Mutz Christopher	Head of Rare Disease	Retenue Fiscale RSU	2,221	$73.90	$164.13K	103,925
2026-02-28	Gassert Chad	SVP - Corp. Dev. & Strategy	Retenue Fiscale RSU	2,221	$73.90	$164.13K	74,916
2026-02-28	Cook Meredith	Sr. VP, General Counsel & Sec.	Retenue Fiscale RSU	1,555	$73.90	$114.91K	79,890
2026-02-28	Davis Krista	SVP, Chief HR Officer	Retenue Fiscale RSU	1,555	$73.90	$114.91K	58,518
2026-02-26	Rowland Thomas Andrew	SVP, Head - Established Brands	Attribution de RSU	6,021	$77.15	$464.52K	44,130
2026-02-26	Carey Stephen P.	SVP & CFO	Attribution de RSU	22,233	$77.15	$1.72M	192,316
2026-02-26	Lalwani Nikhil	President & CEO	Attribution de RSU	75,592	$77.15	$5.83M	434,166
2026-02-26	Gutwerg Ori	SVP, Generics	Attribution de RSU	12,969	$77.15	$1M	89,063
2026-02-26	Mutz Christopher	Head of Rare Disease	Attribution de RSU	21,306	$77.15	$1.64M	106,146
2026-02-26	Shanmugam Muthusamy	Head of R&d, COO-novitium Ops	Attribution de RSU	11,116	$77.15	$857.6K	101,056
2026-02-26	Gassert Chad	SVP - Corp. Dev. & Strategy	Attribution de RSU	11,116	$77.15	$857.6K	77,137
2026-02-26	Cook Meredith	Sr. VP, General Counsel & Sec.	Attribution de RSU	13,895	$77.15	$1.07M	81,445
2026-02-26	Davis Krista	SVP, Chief HR Officer	Attribution de RSU	10,810	$77.15	$833.99K	60,073
2026-02-20	Mutz Christopher	Head of Rare Disease	Vente Informative	5,323	$78.02	$415.3K	84,840
2026-02-20	Davis Krista	SVP, Chief HR Officer	Vente Informative	1,730	$77.99	$134.92K	49,263
2026-02-19	Davis Krista	SVP, Chief HR Officer	Vente Informative	2,084	$77.53	$161.57K	50,993
2026-02-14	Rowland Thomas Andrew	SVP, Head - Established Brands	Retenue Fiscale RSU	485	$77.36	$37.52K	38,109
2026-02-14	Carey Stephen P.	SVP & CFO	Retenue Fiscale RSU	2,448	$77.36	$189.38K	170,083
2026-02-14	Lalwani Nikhil	President & CEO	Retenue Fiscale RSU	10,298	$77.36	$796.65K	358,574
2026-02-14	Gutwerg Ori	SVP, Generics	Retenue Fiscale RSU	1,888	$77.36	$146.06K	76,094
2026-02-14	Mutz Christopher	Head of Rare Disease	Retenue Fiscale RSU	2,403	$77.36	$185.9K	90,163
2026-02-14	Gassert Chad	SVP - Corp. Dev. & Strategy	Retenue Fiscale RSU	1,717	$77.36	$132.83K	66,021
2026-02-14	Cook Meredith	Sr. VP, General Counsel & Sec.	Retenue Fiscale RSU	1,779	$77.36	$137.62K	67,550
2026-02-14	Davis Krista	SVP, Chief HR Officer	Retenue Fiscale RSU	1,290	$77.36	$99.79K	53,077
2026-02-13	Cook Meredith	Sr. VP, General Counsel & Sec.	Vente Informative	500	$76.80	$38.4K	69,329
2026-02-12	Rowland Thomas Andrew	SVP, Head - Established Brands	Retenue Fiscale RSU	566	$76.70	$43.41K	38,594
2026-02-12	Carey Stephen P.	SVP & CFO	Retenue Fiscale RSU	2,829	$76.70	$216.98K	172,531
2026-02-12	Lalwani Nikhil	President & CEO	Retenue Fiscale RSU	11,688	$76.70	$896.47K	368,872
2026-02-12	Gutwerg Ori	SVP, Generics	Retenue Fiscale RSU	1,775	$76.70	$136.14K	77,982
2026-02-12	Mutz Christopher	Head of Rare Disease	Vente Informative	7,032	$76.55	$538.3K	92,566
2026-02-12	Gassert Chad	SVP - Corp. Dev. & Strategy	Retenue Fiscale RSU	1,608	$76.70	$123.33K	67,738

■ Informatif — transaction sur marché ouvert (la plus significative) ■ Non informatif (achat) — récompense, exercice d'option, conversion ■ Non informatif (vente) — retenue fiscale, vente à l'acquisition ■ Neutre — don, fiducie, expiration